Tango Therapeutics Inc. [NASDAQ: TNGX] jumped around 0.67 points on Friday, while shares priced at $7.16 at the close of the session, up 10.32%. The company report on August 29, 2023 at 5:08 PM that Tango Therapeutics Announces Updates to Its Board of Directors.
“The addition of John Ketchum to our Board of Directors comes at an important time for Tango as we advance our pipeline of novel precision oncology treatments, including three programs in phase 1/2 clinical trials. John’s deep global commercial experience in oncology will be tremendously valuable as we continue to evolve the Company, and complementary to the current expertise represented across our Board,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “In addition, I want to thank Aaron for the important role he has played in building Tango and for his strong commitment to the company going forward. Since joining the Board in 2019, Aaron has contributed substantially to the company’s growth, from leading our Series B financing, facilitating our transition to a public company and investing in our recent private placement financing.”.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Tango Therapeutics Inc. stock is now -1.24% down from its year-to-date (YTD) trading value. TNGX Stock saw the intraday high of $7.21 and lowest of $6.4307 per share. The company’s 52-week high price is 9.39, which means current price is +189.88% above from all time high which was touched on 08/09/23.
Compared to the average trading volume of 1.65M shares, TNGX reached a trading volume of 487640 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Tango Therapeutics Inc. [TNGX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNGX shares is $16.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNGX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Tango Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 20, 2022.
The Average True Range (ATR) for Tango Therapeutics Inc. is set at 0.70, with the Price to Sales ratio for TNGX stock in the period of the last 12 months amounting to 19.58. The Price to Book ratio for the last quarter was 2.97, with the Price to Cash per share for the same quarter was set at 3.37.
How has TNGX stock performed recently?
Tango Therapeutics Inc. [TNGX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.99. With this latest performance, TNGX shares gained by 111.21% in over the last four-week period, additionally plugging by 33.58% over the last 6 months – not to mention a rise of 74.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNGX stock in for the last two-week period is set at 62.39, with the RSI for the last a single of trading hit 60.57, and the three-weeks RSI is set at 62.87 for Tango Therapeutics Inc. [TNGX]. The present Moving Average for the last 50 days of trading for this stock 4.67, while it was recorded at 6.95 for the last single week of trading, and 5.20 for the last 200 days.
Tango Therapeutics Inc. [TNGX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Tango Therapeutics Inc. [TNGX] shares currently have an operating margin of -446.79 and a Gross Margin at +83.80. Tango Therapeutics Inc.’s Net Margin is presently recorded at -435.14.
Return on Total Capital for TNGX is now -34.88, given the latest momentum, and Return on Invested Capital for the company is -34.15. Return on Equity for this stock declined to -36.41, with Return on Assets sitting at -22.73. When it comes to the capital structure of this company, Tango Therapeutics Inc. [TNGX] has a Total Debt to Total Equity ratio set at 16.49. Additionally, TNGX Total Debt to Total Capital is recorded at 14.15, with Total Debt to Total Assets ending up at 9.11. Long-Term Debt to Equity for the company is recorded at 15.78, with the Long-Term Debt to Total Capital now at 13.54.
Reflecting on the efficiency of the workforce at the company, Tango Therapeutics Inc. [TNGX] managed to generate an average of -$983,418 per employee. Receivables Turnover for the company is 12.43 with a Total Asset Turnover recorded at a value of 0.05.Tango Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.00.
Insider trade positions for Tango Therapeutics Inc. [TNGX]
The top three institutional holders of TNGX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in TNGX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in TNGX stock with ownership which is approximately 5.7381%.
